Company / Tangible Book Value per Share
UroGen Pharma Ltd. Tangible Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
-$2.50
FY2025
5-year range
-$3.86 / $0.38
FY2021-FY2025
Trend
-24.4%
vs FY2024
Sector context
#196 of 209
Health Care
What the data says
Among 209 Health Care companies, UroGen Pharma Ltd. is in the bottom 6% for tangible book value per share. Tangible Book Value per Share has fluctuated over the past 10 years, ranging from $-3.86 in FY2023 to $8.58 in FY2020.
Based on SEC 10-K filings.
-2.50 in FY2025.
Improved from $-3.86 to $-2.50 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 209This company -$2.50 Sector average $93.47
▼
-102.7% below sector average
Key checks
Key Insights
- In FY2025, tangible book value per share decreased 24.4% year-over-year.
- Ranks #196 out of 209 companies in the Health Care sector.
- Peak tangible book value per share was recorded in FY2020.
- Lowest tangible book value per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.50 | -24.4% |
| FY2024 | -$2.01 | +48.0% |
| FY2023 | -$3.86 | -1131.5% |
| FY2022 | $0.37 | -1.3% |
| FY2021 | $0.38 | -95.6% |
| FY2020 | $8.58 | +54.3% |
| FY2019 | $5.56 | -15.2% |
| FY2018 | $6.55 | -7.1% |
| FY2017 | $7.05 | -0.3% |
| FY2016 | $7.07 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026